Deakin University
Browse

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies

Version 2 2024-06-19, 21:49
Version 1 2023-10-10, 05:18
journal contribution
posted on 2024-06-19, 21:49 authored by RL Bromley, M Bickle Graz, M Bluett-Duncan, C Chambers, P Damkier, K Dietrich, H Dolk, K Grant, S Mattson, KJ Meador, H Nordeng, TF Oberlander, A Ornoy, A Revet, J Richardson, J Rovet, L Schuler-Faccini, E Smearman, V Simms, C Vorhees, K Wide, Amanda WoodAmanda Wood, L Yates, E Ystrom, TA Supraja, J Adams
Background: Exposure in utero to certain medications can disrupt processes of fetal development, including brain development, leading to a continuum of neurodevelopmental difficulties. Recognizing the deficiency of neurodevelopmental investigations within pregnancy pharmacovigilance, an international Neurodevelopmental Expert Working Group was convened to achieve consensus regarding the core neurodevelopmental outcomes, optimization of methodological approaches and barriers to conducting pregnancy pharmacovigilance studies with neurodevelopmental outcomes.Methods: A modified Delphi study was undertaken based on stakeholder and expert input. Stakeholders (patient, pharmaceutical, academic and regulatory) were invited to define topics, pertaining to neurodevelopmental investigations in medication-exposed pregnancies. Experts were identified for their experience regarding neurodevelopmental outcomes following medicinal, substances of misuse or environmental exposures in utero. Two questionnaire rounds and a virtual discussion meeting were used to explore expert opinion on the topics identified by the stakeholders.Results: Twenty-five experts, from 13 countries and professionally diverse backgrounds took part in the development of 11 recommendations. The recommendations focus on the importance of neurodevelopment as a core feature of pregnancy pharmacovigilance, the timing of study initiation and a core set of distinct but interrelated neurodevelopmental skills or diagnoses which require investigation. Studies should start in infancy with an extended period of investigation into adolescence, with more frequent sampling during rapid periods of development. Additionally, recommendations are made regarding optimal approach to neurodevelopmental outcome measurement, comparator groups, exposure factors, a core set of confounding and mediating variables, attrition, reporting of results and the required improvements in funding for potential later emerging effects. Different study designs will be required depending on the specific neurodevelopmental outcome type under investigation and whether the medicine in question is newly approved or already in widespread use.Conclusion: An improved focus on neurodevelopmental outcomes is required within pregnancy pharmacovigilance. These expert recommendations should be met across a complementary set of studies which converge to form a comprehensive set of evidence regarding neurodevelopmental outcomes in pregnancy pharmacovigilance.

History

Journal

Frontiers in Pharmacology

Volume

14

Pagination

1-14

Location

Lausanne, Switzerland

ISSN

1663-9812

eISSN

1663-9812

Language

eng

Publication classification

C1 Refereed article in a scholarly journal

Publisher

Frontiers Media

Usage metrics

    Research Publications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC